Han Yong, Chen Min, Wang Hangzhou
Department of Neurosurgery, Children's Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China.
Exp Ther Med. 2021 Feb;21(2):108. doi: 10.3892/etm.2020.9540. Epub 2020 Nov 27.
Tumor driver genes are genes where structural or sequence mutations confer a selective advantage for cancer cells. The individualized targeting of tumor driver genes has become a topic of interest for tumor treatment. The prognosis for medulloblastoma (MB), a common type of malignant intracranial tumor found in children, is poor. The tumor driver genes and the corresponding targeted drugs remain to be studied. The present study analyzed tumor driver genes from tumor tissue and peripheral blood from one patient with nodular desmoplastic MB with Sonic Hedgehog activation and screened targeted drugs for the tumor driver genes. Additionally, MB tissue was successfully implanted into the SCID mouse which were then used for subsequent drug screening. The present study explored novel treatments for MB from the perspective of tumor driver genes, and may provide new ideas for choosing individualized targeted therapies for patients with MB.
肿瘤驱动基因是指其结构或序列突变能赋予癌细胞选择性优势的基因。对肿瘤驱动基因进行个体化靶向治疗已成为肿瘤治疗领域的一个研究热点。髓母细胞瘤(MB)是儿童常见的一种恶性颅内肿瘤,预后较差。其肿瘤驱动基因及相应的靶向药物仍有待研究。本研究分析了1例具有 Sonic Hedgehog 激活的结节性促结缔组织增生性MB患者的肿瘤组织和外周血中的肿瘤驱动基因,并筛选了针对这些肿瘤驱动基因的靶向药物。此外,成功将MB组织植入SCID小鼠体内,随后用于后续的药物筛选。本研究从肿瘤驱动基因的角度探索了MB的新治疗方法,可能为MB患者选择个体化靶向治疗提供新的思路。